Head and Neck Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
8980 Tissue Procurement and Laboratory Core
15410A Utilization of Previously Banked Tissues from Patients with Head and Neck and Lung Cancer for Analysis of DNA repair markers and Correlation With Clinical Data
Select
11-0265 Randomized Placebo- Controlled Phase II Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesion of the Head and Neck
Select
12-1554 Nab-Paclitaxel-based re-induction chemotherapy followed by response-stratified chemoradiotherapy in patients with previously treated squamous cell carcinoma of the head and neck.
Select
12-1712 A091101: TPF Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Select
IRB13-0936 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0212 An Open Label, Randomized Phase III Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Select
IRB14-0639 Phase II trial of Nab-paclitaxel based induction chemotherapy followed by response-stratified locoregional therapy for patients with stage III and IV HPV-related Oropharyngeal Cancer - the OPTIMA HPV Trial
IRB14-0905 Head and neck MRI for HPV+ oral squamous cell carcinoma before and after treatment: A branch of the OPTIMA trial
Select
IRB14-1547 A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Select
IRB15-0835 A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma
IRB15-1022 A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients with Locally Advanced or Metastatic Solid Tumors
Select
IRB15-1024 A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
Select
IRB15-1130 Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team